Variability in platelet responsiveness to clopidogrel among 544 individuals.
about
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomicsPharmacotherapy in the cardiac catheterization laboratory: evolution and recent developmentsThe role of antiplatelet therapy in the management of acute coronary syndromesFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesAspirin resistance: an evaluation of current evidence and measurement methodsTherapeutic approaches in arterial thrombosisResistance to antiplatelet drugs: current status and future researchThe variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Medications for the treatment of acute coronary syndromesAspirin and clopidogrel resistance: an emerging clinical entityHigh post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndromeSuspected clopidogrel resistance in a patient with acute stent thrombosisResponse to aspirin and clopidogrel monitored with different platelet function methodsClopidogrel resistance: myth or reality?Optimizing platelet P2Y12 inhibition for patients undergoing PCIClopidogrel in the treatment of ischaemic heart diseaseAntiplatelet therapy in populations at high risk of atherothrombosisPlatelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO studyEvaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?Impact of aspirin and clopidogrel interruption on platelet function in patients undergoing major vascular surgeryClopidogrel: the data, the experience, and the controversies.Frequency of heparin/platelet factor 4-dependent platelet antibodies in patients undergoing angioplasty and stenting for cardiovascular disease and their role for on-clopidogrel platelet reactivity.Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement.Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry.The impact of generic clopidogrel bisulfate on platelet inhibition in patients with coronary artery stents: results of the ACCEL-GENERIC studyCytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction.Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?Clopidogrel "resistance": where are we now?Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese populationPrevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala.Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Cytochrome P450 2C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease.Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).
P2860
Q26822796-548B5179-76A7-43AF-9901-FD0DBA88E550Q26862694-E76AE818-EA72-42D9-9280-C88906D73523Q28176548-891E2777-6C90-4B60-9CAE-13583556580EQ28182631-B9077C4C-2B47-4AF9-BB9A-B4448D17C318Q28183220-CF16168B-5C3C-4E18-AD80-8C73E59C1241Q28187576-618A88BA-39B2-45E3-B675-88B20B9574C6Q28192298-9519EFAA-A569-43D3-9840-C949860EEE60Q28192919-22D97CC6-BCF6-4AC5-8DE2-644FC7FC1755Q28193674-5B09F113-F81C-41E2-B1F9-B917B22CE459Q28194021-BE582DB1-9005-454E-A739-68A23E21AAA7Q28194081-77175A45-67BB-4641-AED7-BB0109CF5216Q28196159-EB2BBCD7-D21B-47DA-A542-531D4EE14DD0Q28200256-51198252-F91D-4C24-AEB6-6158C88D8100Q28218055-B82605F1-D6B1-4616-B0D4-9101ACD8E01CQ28218094-E8341C87-4FC2-435A-AA94-33357F61A97EQ28218576-D7AC207D-32F5-442B-8FEF-51739AFC2393Q28218702-7E6BADBD-5A12-4EE1-8C99-A539FA33FA62Q28218790-D9492B8E-0449-4846-9C33-45F075CCEEFFQ28221921-AE4170F3-8199-468E-B089-5F49D381F582Q28542407-B33FAF5F-A038-4AC3-9546-632826BF3233Q30573045-B9349971-02A7-4E05-832B-DD766FA9EB57Q33399119-11D2E94A-9219-4E92-87FE-FAAEE6CA21A6Q33516375-68216CB5-8F03-4E4C-994A-9D3D36A97754Q33554381-4E8C5C5B-BF3F-454B-AEDC-5274899EFB40Q33569289-233F4918-74CB-42ED-9A9B-1EC108B959D0Q33636020-81B47FD4-7089-4DCB-8F4A-7215188C7AA0Q33865395-EA135FD4-AF47-46E4-914A-9A69445E12A0Q33893919-7FCADE64-E7AF-4FF6-8CFF-C7127858BA8DQ33923341-7509D770-CB73-4C1C-8638-D1F4F883866DQ34019342-DDFC94E5-62B2-4CFE-B777-9B634D60C7B1Q34035039-7B66561C-6312-49BC-A2EE-F45DB37F5F98Q34212563-3223C8FC-0350-4E17-8DD7-ED106EAA4E43Q34314265-851CC913-68C2-478A-987F-D7CDB1990FF2Q34494596-091E8CEC-50C1-4634-A195-251B7027BFFAQ34568130-CD7220BC-EF67-436B-9DC4-4AC7DEBE1EA3Q34716730-9FF73B94-FB2E-4225-86F3-75F613D6C0FBQ34763870-0F3B7E7E-F4BE-4F7E-BACD-C6C0ADA9F271Q34771381-9045F359-A646-4531-879D-5D8BC4618488Q35176276-A9943347-5A2E-41BF-A2B3-D4FDEA5B4640Q35208684-5DE0A293-EDA8-42A4-8FC2-F5452A1C9BBF
P2860
Variability in platelet responsiveness to clopidogrel among 544 individuals.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Variability in platelet responsiveness to clopidogrel among 544 individuals.
@en
type
label
Variability in platelet responsiveness to clopidogrel among 544 individuals.
@en
prefLabel
Variability in platelet responsiveness to clopidogrel among 544 individuals.
@en
P50
P1476
Variability in platelet responsiveness to clopidogrel among 544 individuals.
@en
P2093
Alex I Malinin
Victor L Serebruany
P304
P356
10.1016/J.JACC.2004.09.067
P407
P577
2005-01-01T00:00:00Z